ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1717

One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center
Abstract Number: 0249

Open-label, Long-term (10-year) Study of the Safety of Etanercept in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis
Abstract Number: 0375

Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration
Abstract Number: 1065

Optimizing Joint Pain EConsult Referrals in an Underserved Region of Southern California
Abstract Number: 0649

Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
Abstract Number: 0228

Optimizing Social Media as a Recruitment Tool for Hard-to-Reach Populations in Rheumatology Clinical Research
Abstract Number: 1471

Oral Administration of Berberine Limits Post-traumatic Osteoarthritis Development and Associated Pain via AMP-activated Protein Kinase (AMPK) in Mice
Abstract Number: 1021

Organic Dust Exposure Induces Post-translational Protein Modifications and a HLA-DR4-dependent Pro-inflammatory Lung Phenotype in a Murine Model of Interstitial Lung Disease
Abstract Number: 1130

Osteoarthritis Patients Feel Their Tissue Remodeling
Abstract Number: 1134

Osteoarthritis Risk Is Increased in Patients with Atopic Disease
Abstract Number: 1017

Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model
Abstract Number: 1135

Osteoporosis Assessment and Outcomes in Candidates for Liver Transplantation in a Tertiary Center
Abstract Number: 1325

Osteoporosis in Psoriatic Arthritis
Abstract Number: 0097

Outcome of SARS-CoV-2 Infection in Patients with Rheumatoid Arthritis Under Treatment with Janus Kinase Inhibitors Compared to Tumour Necrosis Factor Inhibitors
Abstract Number: 0758

Outcome Reporting in Self-management Interventions for Inflammatory Arthritis Trials: A Systematic Review of Outcome Measures Covering Self-management Domains

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].